Immune checkpoint inhibitors and cardiovascular toxicity.
Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J.
Lancet Oncol. 2018 Sep;19(9):e447-e458. doi: 10.1016/S1470-2045(18)30457-1.
The 2015 WHO Classification of Tumors of the Heart and Pericardium.
Burke A, Tavora F.
J Thorac Oncol. 2016 Apr;11(4):441-52. doi: 10.1016/j.jtho.2015.11.009. Epub 2015 Dec 25.
Involvement of the heart by malignant lymphoma: a clinicopathologic study.
McDonnell PJ, Mann RB, Bulkley BH.
Cancer. 1982 Mar 1;49(5):944-51. doi: 10.1002/1097-0142(19820301)49:5<944::aid-cncr2820490519>3.0.co;2-c.
The effects of radiation therapy on the heart: implications for management.
Hsieh K, Hotca AE, Runnels J, Cherry D, Bloom JR, Yu C, Nehlsen AD, Resende Salgado L, Sindhu KK.
Chin Clin Oncol. 2024 Feb;13(1):10. doi: 10.21037/cco-23-125. Epub 2024 Feb 20.
Spectrum of malignant pleural and pericardial disease on FDG PET/CT.
Makis W, Ciarallo A, Hickeson M, Rush C, Novales-Diaz JA, Derbekyan V, Laufer J, Stern J, Lisbona R.
AJR Am J Roentgenol. 2012 Mar;198(3):678-85. doi: 10.2214/AJR.11.7076.
Cardiac metastases.
Bussani R, De-Giorgio F, Abbate A, Silvestri F.
J Clin Pathol. 2007 Jan;60(1):27-34. doi: 10.1136/jcp.2005.035105. Epub 2006 Nov 10.
[Asymptomatic course of rhabdomyoma of the heart].
Chepurnenko SA, Nasytko AD, Shavkuta GV.
Kardiologiia. 2023 Aug 31;63(8):68-72. doi: 10.18087/cardio.2023.8.n1821.
Oncometabolic Tracks in the Heart.
Taegtmeyer H, Karlstaedt A, Rees ML, Davogustto G.
Circ Res. 2017 Jan 20;120(2):267-269. doi: 10.1161/CIRCRESAHA.116.310115.
Secondary malignant lesions of the heart and pericardium in neoplastic disease.
Skhvatsabaja LV.
Oncology. 1986;43(2):103-6. doi: 10.1159/000226344.
The effect of malignant neoplasms on the heart. A study on the electrocardiographic abnormalities and the anatomical findings in cases with and without cardiac involvement.
Nakamura A, Suchi T, Mizuno Y.
Jpn Circ J. 1975 May;39(5):531-42. doi: 10.1253/jcj.39.531.
